Amgen gives first glimpse at PRMT5 inhibitor, days after Bristol Myers put a $1B promise on the target
In a first look at Amgen’s experimental PRMT5 inhibitor, roughly 16% of patients with various cancers saw their tumors shrink by at least 30%, equating to a partial response.
The results come as the target has been garnering greater attention. On Sunday, Bristol Myers Squibb promised a potential $1 billion in additional payments to Mirati shareholders related to the biotech’s PRMT5 inhibitor as part of its proposed acquisition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
